Immunogenicity of HPV Vaccine in Immunosuppressed Children

PHASE3CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

February 29, 2016

Study Completion Date

December 31, 2016

Conditions
Autoimmune DiseaseJuvenile Idiopathic ArthritisInflammatory Bowel DiseaseEvidence of Liver TransplantationKidney Transplant InfectionBone Marrow Transplant Infection
Interventions
BIOLOGICAL

Quadrivalent HPV vaccine

Three 0.5 mL doses will be given at time 0, 2 months after the 1st dose and then 6 months after the initial dose. For kidney transplant recipients the first dose will be at least 6 months post-transplant.

Trial Locations (1)

2052

School of Public Health and Community Medicine, Sydney

All Listed Sponsors
collaborator

Sydney Children's Hospitals Network

OTHER

collaborator

Women's and Children's Hospital, Australia

OTHER_GOV

lead

The University of New South Wales

OTHER

NCT02263703 - Immunogenicity of HPV Vaccine in Immunosuppressed Children | Biotech Hunter | Biotech Hunter